A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 19 Nov 2018
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2018 Planned number of patients changed from 58 to 86.
- 06 Jun 2018 Status changed from not yet recruiting to recruiting.
- 28 May 2018 New trial record